- Home
- ITRG vs BCAB Comparison
ITRG vs BCAB Comparison
Compare ITRG & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRG
- BCAB
- Stock Information
- Founded
- ITRG 1997
- BCAB 2007
- Country
- ITRG Canada
- BCAB United States
- Employees
- ITRG N/A
- BCAB N/A
- Industry
- ITRG Precious Metals
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- ITRG Basic Materials
- BCAB Health Care
- Exchange
- ITRG Nasdaq
- BCAB Nasdaq
- Market Cap
- ITRG 84.2M
- BCAB 96.2M
- IPO Year
- ITRG N/A
- BCAB 2020
- Fundamental
- Price
- ITRG $1.20
- BCAB $2.08
- Analyst Decision
- ITRG Strong Buy
- BCAB Strong Buy
- Analyst Count
- ITRG 1
- BCAB 2
- Target Price
- ITRG $3.75
- BCAB $6.00
- AVG Volume (30 Days)
- ITRG 259.4K
- BCAB 1.6M
- Earning Date
- ITRG 11-12-2024
- BCAB 11-08-2024
- Dividend Yield
- ITRG N/A
- BCAB N/A
- EPS Growth
- ITRG N/A
- BCAB N/A
- EPS
- ITRG N/A
- BCAB N/A
- Revenue
- ITRG N/A
- BCAB N/A
- Revenue This Year
- ITRG N/A
- BCAB N/A
- Revenue Next Year
- ITRG $360.53
- BCAB N/A
- P/E Ratio
- ITRG N/A
- BCAB N/A
- Revenue Growth
- ITRG N/A
- BCAB N/A
- 52 Week Low
- ITRG $0.64
- BCAB $1.14
- 52 Week High
- ITRG $1.28
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- ITRG 66.49
- BCAB 55.80
- Support Level
- ITRG $0.95
- BCAB $1.87
- Resistance Level
- ITRG $1.28
- BCAB $2.13
- Average True Range (ATR)
- ITRG 0.07
- BCAB 0.12
- MACD
- ITRG 0.01
- BCAB 0.00
- Stochastic Oscillator
- ITRG 77.27
- BCAB 68.90
About ITRG Integra Resources Corp.
Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of highly prospective early-stage exploration projects in Idaho, Nevada, and Arizona.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.